Quick Answer
BIODESIX INC reported Total Revenue of $88.50 million for fiscal year 2025.
BIODESIX INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $88.50M +24.1% |
$71.32M +45.3% |
$49.09M +28.5% |
$38.21M -29.9% |
$54.51M +19.6% |
$45.56M +85.6% |
| Net Income | -$35.27M +17.9% |
-$42.93M +17.7% |
-$52.15M +20.3% |
-$65.45M -51.6% |
-$43.16M +34.1% |
-$65.45M -113.0% |
| Diluted EPS | -$4.67 +29.7% |
-$6.64 -937.5% |
-$0.64 +58.7% |
-$1.55 +1.9% |
-$1.58 | — |
| Total Assets | $87.48M -10.0% |
$97.24M -1.9% |
$99.10M +6.7% |
$92.91M +22.1% |
$76.10M -37.1% |
$121.07M +168.8% |
| Cash and Equivalents | $18.99M -27.7% |
$26.25M -0.1% |
$26.28M -39.0% |
$43.09M +31.7% |
$32.71M -47.3% |
$62.13M +1075.3% |
| Stockholders Equity | -$2.46M -111.8% |
$20.88M +355.8% |
$4.58M -77.8% |
$20.61M +4.5% |
$19.73M -52.1% |
$41.17M +118.3% |
| R&D Expense | $12.00M +25.5% |
$9.56M -4.3% |
$9.99M -23.8% |
$13.10M +2.4% |
$12.79M +18.2% |
$10.82M +3.3% |
| Operating Income | -$27.87M +19.2% |
-$34.50M +16.6% |
-$41.34M +18.3% |
-$50.59M -23.6% |
-$40.94M -78.5% |
-$22.93M +14.2% |
| Shares Outstanding | 8.25M +13.5% |
7.27M -92.4% |
96.24M +24.0% |
77.61M +152.1% |
30.79M +15.9% |
26.56M +10319.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $21.77M | +19.9% | +8.7% |
| Net Income | September 30, 2025 | -$8.72M | +15.0% | +24.0% |
| Diluted EPS | September 30, 2025 | -$1.16 | +17.1% | -1350.0% |
| Total Assets | September 30, 2025 | $88.72M | -13.6% | +1.1% |
| Cash and Equivalents | September 30, 2025 | $16.60M | -47.1% | -19.9% |
| Stockholders Equity | September 30, 2025 | -$1.72M | -106.2% | -251.3% |
| R&D Expense | September 30, 2025 | $2.99M | +17.5% | -8.5% |
| Operating Income | September 30, 2025 | -$7.05M | +17.9% | +27.5% |
| Shares Outstanding | September 30, 2025 | 7.95M | -94.5% | -94.6% |
- BIODESIX INC reported Total Revenue of $88.50 million for fiscal year 2025.
- BIODESIX INC showed an increase of +24.1% in Total Revenue compared to the prior fiscal year.
- BIODESIX INC reported Net Income of -$35.27 million for fiscal year 2025.
- BIODESIX INC showed an increase of +17.9% in Net Income compared to the prior fiscal year.
- BIODESIX INC reported Diluted EPS of $4.67 per share (loss) for fiscal year 2025.
- BIODESIX INC showed an increase of +29.7% in Diluted EPS compared to the prior fiscal year.
- BIODESIX INC reported Total Assets of $87.48 million for fiscal year 2025.
- BIODESIX INC showed a decrease of -10.0% in Total Assets compared to the prior fiscal year.
- BIODESIX INC reported Cash and Equivalents of $18.99 million for fiscal year 2025.
- BIODESIX INC showed a decrease of -27.7% in Cash and Equivalents compared to the prior fiscal year.
- BIODESIX INC reported Stockholders Equity of -$2.46 million for fiscal year 2025.
- BIODESIX INC showed a decrease of -111.8% in Stockholders Equity compared to the prior fiscal year.
- BIODESIX INC reported R&D Expense of $12.00 million for fiscal year 2025.
- BIODESIX INC showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- BIODESIX INC reported Operating Income of -$27.87 million for fiscal year 2025.
- BIODESIX INC showed an increase of +19.2% in Operating Income compared to the prior fiscal year.
- BIODESIX INC reported Shares Outstanding of 8.25 million shares for fiscal year 2025.
- BIODESIX INC showed an increase of +13.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: